Read Original Story

WSJ’s look at stent study: Solid reporting, with room for more detail on costs and risks


4 Star

Study Raises Questions About Stents in Some Heart Patients

Our Review Summary

This Wall Street Journal story describes surprising news that a very common procedure– inserting a stent to open a blocked blood vessel — does not add benefit over medication in patients with angina. Angina is chest pain due to blocked heart arteries, and is common among people with heart disease.

One strength of the story is the detailed description of the study itself and in finding outside sources to critique aspects of the study. We do think the cost of the procedure was worth discussion, as well as the potential harms, but they were not addressed in this story. These points were raised in the New York Times story, which we also reviewed.


Why This Matters

Heart disease is still the leading killer of Americans so any news about treating aspects of heart disease, such as blocked arteries, is newsworthy. In addition, this story suggests that stenting — common, but expensive — is a prime example of over-treatment.


Does the story adequately discuss the costs of the intervention?

Not Satisfactory

The story does not mention the cost of stent insertion, which can run into the tens of thousands of dollars.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?


The story describes the main outcome measure — how long subjects could exercise on a treadmill before experiencing pain — and the change in exercise duration — a 28 second improvement after stent insertion versus 12 second improvement after sham surgery. Readers are told that no statistical difference exists between those averages.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

The story does not mention harms of the procedure, which should be a factor in weighing the risks and benefits of any intervention.

Does the story seem to grasp the quality of the evidence?


The story describes the study’s size and methods and goes into some depth about how the sham procedure can control for placebo effects. Limitations were discussed, as well. The story also provides some critiques from outside sources, including the fact that study subjects, with only one major blockage, do not represent the majority of patients to whom doctors recommend stents.

Does the story commit disease-mongering?


No disease mongering here. It was good to see the story discuss the concerns around over-use of stents.

Does the story use independent sources and identify conflicts of interest?


The story quotes one of the study authors and authors of an accompanying commentary in the journal, The Lancet. The reporter also sought comment from stent makers, who were mostly critical of the study — but these potential conflicts were made clear to readers.

Does the story compare the new approach with existing alternatives?


The story, in describing the study, makes clear that management of angina pain with medication is equally effective in these kinds of patients.

Does the story establish the availability of the treatment/test/product/procedure?


The story makes clear that stent insertion is widely available and frequently done.

Does the story establish the true novelty of the approach?


The story makes clear that what is novel about this research is the use of a placebo group whose participants underwent procedures but didn’t receive a stent.

Does the story appear to rely solely or largely on a news release?


The story goes well beyond what is contained in the news release from the host institution, Imperial College.

Total Score: 8 of 10 Satisfactory


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.